NCT01490086Phase 2Completed

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Study sponsor: Reviva Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2013-03Actual
Enrollment · participants234Actual
Source updated2025-08-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.